Key result
Mesenchymal stem cell transplantation significantly improved cardiac systolic function and reduced the severity of experimental autoimmune myocarditis in rats.
Why the study?
Does mesenchymal stem cell transplantation improve cardiac function and reduce severity in a rat model of experimental autoimmune myocarditis?
Does mesenchymal stem cell transplantation improve cardiac function and reduce severity in a rat model of experimental autoimmune myocarditis?
Mesenchymal stem cell transplantation reduces the severity of experimental autoimmune myocarditis in rats by inducing neovascularization and inhibiting inflammatory cytokine production, potentially mediated by hepatocyte growth factor.
Answers are grounded in this paper and cite their sources.
Premature for clinical myocarditis use; leaves open translation of stem cell benefits from rat models to humans.
Mesenchymal stem cells (MSCs) have various effects, including angiogenic, myogenic, and paracrine actions. In this study, we determined whether MSC transplantation attenuates experimental autoimmune myocarditis (EAM). The mechanisms involved were also investigated. Male Lewis rats were immunized with myosin to establish EAM on day 0. MSCs, isolated from isogenic rats, were injected directly into the myocardium on day 14 (group MSC-2W), day 21 (group MSC-3W), or day 28 (group MSC-4W). In the MSC transplantation groups, cardiac systolic function detected by echocardiography was significantly improved, the EAM affected area determined by histological examination was significantly decreased, and capillary density was increased compared to that in the control groups. Expression of hepatocyte growth factor protein was enhanced by MSC transplantation. MSC transplantation inhibited myocardial expression of interleukin-2, -6, and -10 mRNAs. MSC transplantation reduces the severity of EAM by inducing neovascularization and inhibiting inflammatory cytokine production. Enhanced expression of hepatocyte growth factor was associated with these effects. Autoimmune myocarditis may be a good clinical target for MSC transplantation.
No takes yet. Share an insight, caveat, or question.
Okada et al. (2007) studied Experimental autoimmune myocarditis (n=48). Mesenchymal stem cell transplantation vs. Vehicle (DMEM alone) or no treatment was evaluated on Cardiac systolic function (left ventricular fractional shortening) and myocarditis-affected area (p=<0.05). Mesenchymal stem cell transplantation significantly improved cardiac systolic function and reduced the severity of experimental autoimmune myocarditis in rats.
Synapse has enriched 10 related papers. Consider them for comparative context: